Vascular BioSciences (VBS) is a biopharmaceutical and medical device company that provides solutions for the treatment of cardiovascular and inflammatory diseases. The company is engaged in pharmaceutical, interventional and molecular diagnostics businesses. Its pharmaceuticals therapies address the fundamental mechanisms and pathways underlying vascular based diseases. VBS develops and manufactures endoarterial biopsy catheter for diagnosis, monitoring and treatment of vascular-based diseases. The company offers its services in the therapeutic areas of wound healing, sepsis, pulmonary hypertension, sepsis and corona disease. VBS is headquartered in Durham, North Carolina, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Vascular BioSciences
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Vascular BioSciences Company Overview
- Vascular BioSciences Company Snapshot
- Vascular BioSciences Pipeline Products and Ongoing Clinical Trials Overview
- Vascular BioSciences - Pipeline Analysis Overview
- Vascular BioSciences - Key Facts
- Vascular BioSciences - Major Products and Services
- Vascular BioSciences Pipeline Products by Development Stage
- Vascular BioSciences Pipeline Products Overview
- EABx - COVID-19
- EABx - COVID-19 Product Overview
- EABx - Lung Transplant Rejection
- EABx - Lung Transplant Rejection Product Overview
- EABx - Pulmonary Arterial Hypertension
- EABx - Pulmonary Arterial Hypertension Product Overview
- Imaging Agent - COVID-19
- Imaging Agent - COVID-19 Product Overview
- Imaging Agent - Pulmonary Hypertension
- Imaging Agent - Pulmonary Hypertension Product Overview
- Imaging Agent - Sepsis
- Imaging Agent - Sepsis Product Overview
- Vascular BioSciences - Key Competitors
- Vascular BioSciences - Key Employees
- Vascular BioSciences - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Vascular BioSciences, Recent Developments
- Jun 03, 2020: Vascular Biosciences announces new preclinical research results demonstrating improved pulmonary hypertension and sepsis survival with car peptide
- Sep 03, 2019: FDA grants Vascular BioSciences humanitarian use device (HUD) designation to the endoarterial biopsy catheter for group 1 pulmonary arterial hypertension
- May 19, 2017: Vascular BioSciences Announces Publication of “Assessment of microRNA and gene dysregulaton in pulmonary hypertension by endoarterial biopsy” in the Current Issue of Pulmonary Circulation
- Apr 10, 2013: Vascular BioSciences announces publication of “Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension” in the Current Issue of Pulmonary Circulation
- Jul 03, 2012: Vascular BioSciences announced that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry
- Jun 27, 2011: Vascular Biosciences announces publication of “Hemodynamic and Histologic Characterization of a Swine (Sus scrofa domestica) Model of Chronic Pulmonary Arterial Hypertension”
- Apr 23, 2011: Vascular BioSciences to Sponsor 2011 Southern California Undergraduate Research Conference in Chemistry and Biochemistry
- Dec 24, 2010: Vascular BioSciences, In Collaboration with the University of South Alabama, Awarded Exploration/Development R21 Grant from the National Heart Lung Blood Institute of the National Institutes of Health for Cell-targeted Drug Delivery for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Jan 08, 2010: Vascular BioSciences Opens New Office and Pilot Catheter Manufacturing Facility in Goleta, California
- Feb 18, 2009: Vascular BioSciences CEO David Mann Awarded New U.S. and European Patents for Endorterial Biopsy Catheterization Equipment Kit Invention
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Vascular BioSciences Pipeline Products and Ongoing Clinical Trials Overview
- Vascular BioSciences Pipeline Products by Equipment Type
- Vascular BioSciences Pipeline Products by Indication
- Vascular BioSciences, Key Facts
- Vascular BioSciences, Major Products and Services
- Vascular BioSciences Number of Pipeline Products by Development Stage
- Vascular BioSciences Pipeline Products Summary by Development Stage
- EABx - COVID-19 - Product Status
- EABx - COVID-19 - Product Description
- EABx - Lung Transplant Rejection - Product Status
- EABx - Lung Transplant Rejection - Product Description
- EABx - Pulmonary Arterial Hypertension - Product Status
- EABx - Pulmonary Arterial Hypertension - Product Description
- Imaging Agent - COVID-19 - Product Status
- Imaging Agent - COVID-19 - Product Description
- Imaging Agent - Pulmonary Hypertension - Product Status
- Imaging Agent - Pulmonary Hypertension - Product Description
- Imaging Agent - Sepsis - Product Status
- Imaging Agent - Sepsis - Product Description
- Vascular BioSciences, Key Employees
- Vascular BioSciences, Other Locations
- Glossary
- Vascular BioSciences Pipeline Products by Equipment Type
- Vascular BioSciences Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Mitralign Inc
- CardioFocus Inc
- Abbott Cardiovascular Systems Inc
- Mogul Enterprises Inc
